Whole genome sequencing

全基因组测序
  • 文章类型: Journal Article
    胎儿结构异常和出生缺陷主要由染色体数目异常等遗传变异引起,拷贝数变异(CNV),单核苷酸变异(SNV),和小插入和删除(indel)。基于下一代测序(NGS)的全基因组测序(WGS)作为一种新兴的遗传病诊断技术,可以检测上述类型的变异。近年来,用于产前诊断的深度WGS(>30×)也已可用,并被证明适用于揭示胎儿发育异常的遗传病因。为了促进临床实践,用于诊断胎儿结构异常的WGS的测试开发和初步实施,我们通过汇编先前发表的共识,就WGS在产前诊断中的应用达成了共识,指导方针,和研究结果,为数据分析提供指导,报告建议,和产前WGS结果咨询。
    Fetal structural anomalies and birth defects are primarily caused by genetic variants such as chromosomal number abnormalities, copy number variations (CNV), single nucleotide variants (SNV), and small insertions and deletions (indel). Whole-genome sequencing (WGS) based on next-generation sequencing (NGS) as an emerging technology for genetic disease diagnosis can detect the aforementioned types of variants. In recent years, high-depth WGS (> 30×) for prenatal diagnosis has also become available, and proved to be practical for unraveling the genetic etiology of fetal developmental abnormalities. To facilitate clinical practice, test development and preliminary implementation of WGS for diagnosing fetal structural anomalies, we have formulated a consensus over the application of WGS in prenatal diagnosis by compiling previously published consensuses, guidelines, and research findings to provide a guidance on data analysis, reporting recommendations, and consultation of prenatal WGS results.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    Objective: To compare the differences between the variation interpretation standards and guidelines issued by the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) in 2015 (The 2015ACMG/AMP guideline) and the Deafness Specialist Group of the Clinical Genome Resource (ClinGen) in 2018 for hereditary hearing loss (Healing loss, HL) issued the expert specification of the variation interpretation guide (The 2018 HL-EP guideline) in evaluating the pathogenicity of OTOF gene variation in patients with auditory neuropathy. Methods: Thirty-eight auditory neuropathy patients with OTOF gene variant were selected as the study subjects (23 males and 15 females, aged 0.3-25.9 years). Using whole-genome sequencing, whole exome sequencing or target region sequencing (Panel) combined with Sanger sequencing, 38 cases were found to carry more than two OTOF mutation sites. A total of 59 candidate variants were independently interpreted based on the 2015 ACMG/AMP guideline and 2018 HL-EP guideline. Compared with the judgment results in 2015 ACMG/AMP guideline, the variants interpreted as lower pathogenic classifications in the 2018 HL-EP guideline were defined as downgraded variants, and the variants regarded as higher pathogenic classifications were defined as upgraded variants. Statistical analysis was conducted using SPSS 20.0. Results: The concordance rate of variant classification between the guidelines was 72.9%(43/59). The 13.6%(8/59) of variants were upgraded and 13.6% (8/59) of variants downgraded in the classifications of the 2018 HL-EP guideline. A couple of rules saw significant differences between the guidelines (PVS1, PM3, PP2, PP3 and PP5). The distribution of pathogenicity of splicing mutation was statistically different (P=0.013). Conclusions: The 2018 HL-EP guideline is inconsistent with the 2015 ACMG/AMP guideline, when judging the pathogenicity of OTOF gene variants in patients with auditory neuropathy. Through the deletion and refinement of evidence and the breaking of solidification thinking, the 2018 HL-EP guideline makes the pathogenicity grading more traceable and improves the credibility.
    目的: 对比2015年美国医学遗传学与基因组学学会(American College of Medical Genetics and Genomics,ACMG)和分子病理学会(Association for Molecular Pathology,AMP)发布的变异解读标准与指南(本文中简称2015 ACMG/AMP指南)与2018年临床基因组资源中心(Clinical Genome Resource,ClinGen)耳聋专病小组针对遗传性听力损失(hearing loss,HL)发布的变异解读指南专家规范(本文中简称2018HL专病指南)在评估听神经病患者OTOF基因变异致病性中的异同。 方法: 以38例OTOF基因变异听神经病患者作为研究对象(男23例、女15例,年龄范围0.3~25.9岁),经全基因组重测序、全外显子组测序或目标区域靶向(Panel)测序结合一代Sanger测序验证,38例听神经病患者均检出携带两个以上OTOF变异位点,共计59个候选位点,分别使用2015ACMG/AMP指南以及2018HL专病指南对其致病性进行判断。与2015年指南判断结果相比,2018年指南判断的致病性等级更强定义为升级,更弱定义为降级。采用SPSS 20.0软件进行统计学分析。 结果: 2015 ACMG/AMP指南和2018 HL专病指南的变异分类一致率为72.9%(43/59)。致病性升级变异位点占13.6%(8/59),致病性降级变异位点占13.6%(8/59)。两指南致病性判定不一致主要集中在PVS1、PM3、PP2、PP3以及PP5等级证据的应用上。剪接变异、错义变异、框内插入/缺失以及同义变异致病性分布发生改变,其中剪接变异改变差异具有统计学意义(P=0.013)。 结论: 针对听神经病患者OTOF基因变异进行致病性判断时,2018HL专病指南与2015ACMG/AMP指南存在不一致,2018HL专病指南对证据进行删减及进一步细分,打破常规对于变异类型的固化思维,使得致病性分级更有迹可循,提高可信度。.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    结核病(TB)是可以预防的,可治疗,和可治愈的疾病。然而,到2020年,估计有900万人患有结核病,估计有150万人因此丧生。而在印度,2019年,260万人被诊断出患有结核病,43.6万人死于结核病。印度(26%)是全球结核病病例下降的主要贡献者。COVID-19大流行大大减少了获得结核病诊断和治疗服务的机会,导致死亡人数增加和全球进步逆转。[1]目前,结核病发病率以每年2%的速度下降,主要是由于耐药结核病(DRTB)的饲养大流行而受阻。尤其令人担忧的是耐多药结核病(MDRTB),定义为对异烟肼(INH)和利福平(RIF)的抗性。[2]世界卫生组织(WHO)的目标是到2035年将全球结核病发病率降低90%。(1)基于结核分枝杆菌复合体(MTBC)的易感性模式的早期开始有效治疗被认为是在DRTB发病率高的国家成功控制结核病的关键。全球MDRTB治疗效果不佳,治愈率低于60%(2)由于缺乏在大多数高MDRTB负担的国家全面的药物敏感性测试(DST)。这导致所提供方案的抗结核活性不足(3-5),与建议用于DST的方案不同,可确保最佳结果。(6)除了抵制既定的方案外,对新型DRTB药物的耐药性正在增加。2022年世界防治结核病日,高等医学教育学院,ThyrocareTechnologiesLimited和HyastackAnalytics-IITB与来自印度的肺科专家和知名医师于2022年3月20日在德里召开了一次咨询委员会会议,讨论了全基因组测序(WGS)在结核病诊断和管理中的作用。讨论了MDRTB中与WGS相关的目标和特定主题,每位专家都分享了他们的观点,这导致了一个小组讨论,承诺把病人放在第一位,增加他们的集体努力,组织认识到有可能实现这一目标。参与讨论的组织已宣布致力于开展合作努力,以有效解决DRTB检测问题。他们主张加强对WGSTB服务的访问,控制和预防结核病,改善监测和耐药性管理,并投资于研发。本圆桌会议是一个框架,可以在需要的地方使用WGS服务来实现并确保终止结核病的目标。Postdiscussion,如果超过80%的董事会成员同意该声明,据说会达成统一的共识。本文是咨询委员会会议上提出和讨论的方面的结果。
    Tuberculosis (TB) is a preventable, treatable, and curable disease. However, in 2020, 9∙9 million people were estimated to have developed tuberculosis, and 1.5 million people were estimated to have died from it. Whereas in India, 2.6 million were diagnosed with TB and 436,000 succumbed to TB in 2019. India (26%) is the major contributor to the global drop in TB cases. The COVID-19 pandemic has substantially reduced access to services for the diagnosis and treatment of TB, resulting in an increase in deaths and a reversal in global progress. [1] Presently, TB incidence is falling at a rate of 2% per year, obstructed mainly by the rearing pandemic of drug-resistant tuberculosis (DRTB). Particularly concerning is multi-drug resistant TB (MDRTB), defined as resistance towards isoniazid (INH) and rifampicin (RIF). [2] The World Health Organization (WHO) targeted to reduce worldwide TB incidence by 90% until 2035. (1) Early initiation of effective treatment based on susceptibility patterns of the Mycobacterium tuberculosis complex (MTBC) is considered key to successful TB control in countries with high DRTB incidence. Worldwide MDRTB treatment outcomes are poor, with cure rates less than 60% (2) due to the lack of comprehensive Drug Susceptibility Testing (DST) in most high MDRTB burden countries. This is leading to the inadequate anti-TB activity of the provided regimens (3-5), unlike regimens advised for DST assure optimal results. (6) In addition to resistances to the established regimens, the resistance to the newer DRTB drugs is increasing. On World TB Day 2022, Academy of Advanced Medical Education, Thyrocare Technologies Limited and HyastackAnalytics - IITB along with expert pulmonologist and renowned physicians from India convened for an advisory board meeting in Delhi on 20th March 2022 to discuss the role of Whole Genome Sequencing (WGS) in the diagnosis and management of TB. Objectives and specific topics relating to WGS in MDRTB were discussed, each expert shared their views, which led to a group discussion with a commitment to putting the patient first, and increasing their collective efforts, the organizations recognized that it is possible to make this goal a reality. The organizations involved in the discussion have declared their commitment to engaging in collaborative efforts to tackle DRTB detection efficiently. They advocate for strengthening access to WGS TB services, controlling and preventing TB, improving surveillance and drug resistance management, and investing in research and development. This Round Table serves as a framework to build on and ensure that the goal of ending TB is achievable with WGS services wherever needed. Post discussion, a uniform consensus was said to be arrived if more than 80% board members agreed to the statement. The present paper is the outcome of aspects presented and discussed in the advisory board meeting.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:大规模平行测序技术,如全外显子组测序(WES)和全基因组测序(WGS),可能会发现与诊断目的无关的未经请求的发现(UF)。这种技术经常用于小儿发育迟缓(DD)病例的诊断目的。然而,知情同意和归还UF的政策指南并没有很好地解决这些儿童处境中可能出现的具体道德挑战。
    结论:在我们研究小组进行的先前实证研究中,我们发现,有时不确定患有DD的儿童将如何发展,以及他们将来是否可以拥有自主决策的能力。在进行三重奏分析(父母和孩子的DNA都被测序)之前,父母有时会觉得在面对UF的选择时,这让他们陷入了Catch-22的境地。选择同意WES的一个重要原因是为了更深入地了解他们的孩子可能会如何发展。然而,对接收或拒绝UF知识做出负责任的选择,需要一些关于他们孩子未来自主能力发展的想法。这种不希望的Catch-22情况是由特定的策略配置造成的,在该策略配置中,要求父母在进行测序(三重分析)之前对UF进行选择。我们认为,这一发现与重新配置当前WES/WGS的UF返回政策有关,并提出包含两个功能的指南。首先,知情同意过程应该分阶段进行。第二,在DD适合儿童未来自主能力发展的信心水平的情况下,扣留/披露UF需要不同的指导方针。
    结论:当与动态同意程序结合使用时,我们指南的这两个特点可以帮助克服在接受基因组测序以澄清DD的儿童中出现的重大道德挑战.
    Massively parallel sequencing techniques, such as whole exome sequencing (WES) and whole genome sequencing (WGS), may reveal unsolicited findings (UFs) unrelated to the diagnostic aim. Such techniques are frequently used for diagnostic purposes in pediatric cases of developmental delay (DD). Yet policy guidelines for informed consent and return of UFs are not well equipped to address specific moral challenges that may arise in these children\'s situations.
    In previous empirical studies conducted by our research group, we found that it is sometimes uncertain how children with a DD will develop and whether they could come to possess capacities for autonomous decision-making in the future. Parents sometimes felt this brought them into a Catch-22 like situation when confronted with choices about UFs before undergoing WES in trio-analysis (both the parents\' and child\'s DNA are sequenced). An important reason for choosing to consent to WES was to gain more insight into how their child might develop. However, to make responsible choices about receiving or declining knowledge of UFs, some idea of their child\'s future development of autonomous capacities is needed. This undesirable Catch-22 situation was created by the specific policy configuration in which parents were required to make choices about UFs before being sequencing (trio-analysis). We argue that this finding is relevant for reconfiguring current policies for return of UFs for WES/WGS and propose guidelines that encompass two features. First, the informed consent process ought to be staged. Second, differing guidelines are required for withholding/disclosing a UF in cases of DD appropriate to the level of confidence there is about the child\'s future developmental of autonomous capacities.
    When combined with a dynamic consent procedure, these two features of our guidelines could help overcome significant moral challenges that present themselves in the situations of children undergoing genomic sequencing for clarifying a DD.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    病毒分离株的全基因组测序对于告知传播模式和病原体的持续进化至关重要。尤其是在大流行期间。然而,当基因组在大流行的早期阶段具有低变异性时,技术和/或测序错误的影响增加。我们定量评估了在悉尼不同实验室测序的72个匹配的SARS-CoV-2阳性标本的共识基因组组装的实验室间差异,澳大利亚。平行使用两个不同的生物信息学管道组装原始序列数据,并对产生的共有基因组进行比较,以检测实验室特异性差异.匹配的基因组序列主要是一致的,成对同一性中位数为99.997%。识别出的差异主要由模棱两可的网站内容驱动。忽略这些在仅2.3%(5/216)的成对比较中产生的差异,每个都有一个核苷酸不同。匹配的样本在98.2%(212/216)的成对比较中被分配相同的Pango谱系,大多被分配到相同的系统发育进化枝。然而,如果实验室之间共有基因组产生的变异等位基因频率阈值不同,则仅基于单核苷酸变异距离的流行病学推断可能会导致定义簇数量的显着差异。这些结果强调了统一的必要性,研究共同爆发问题的实验室之间的生物信息学最佳实践方法。
    Whole-genome sequencing of viral isolates is critical for informing transmission patterns and for the ongoing evolution of pathogens, especially during a pandemic. However, when genomes have low variability in the early stages of a pandemic, the impact of technical and/or sequencing errors increases. We quantitatively assessed inter-laboratory differences in consensus genome assemblies of 72 matched SARS-CoV-2-positive specimens sequenced at different laboratories in Sydney, Australia. Raw sequence data were assembled using two different bioinformatics pipelines in parallel, and resulting consensus genomes were compared to detect laboratory-specific differences. Matched genome sequences were predominantly concordant, with a median pairwise identity of 99.997%. Identified differences were predominantly driven by ambiguous site content. Ignoring these produced differences in only 2.3% (5/216) of pairwise comparisons, each differing by a single nucleotide. Matched samples were assigned the same Pango lineage in 98.2% (212/216) of pairwise comparisons, and were mostly assigned to the same phylogenetic clade. However, epidemiological inference based only on single nucleotide variant distances may lead to significant differences in the number of defined clusters if variant allele frequency thresholds for consensus genome generation differ between laboratories. These results underscore the need for a unified, best-practices approach to bioinformatics between laboratories working on a common outbreak problem.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    暂无摘要。
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    在我们的三级护理中心,据报道,大肠杆菌血液分离株对阿莫西林/克拉维酸的敏感性在2005年超过90%,到2017年逐渐下降至50%.在这项研究中,我们调查了耐药大肠杆菌菌株是否真正增加,或者报告的敏感性明显下降是否归因于2014年EUCAST指南对CLSI的替代.我们从1985年到2018年随机选择了237种大肠杆菌血液分离物(储存在-80°C),并重新评估了它们的MIC值。同时应用CLSI(克拉维酸的固定比例)和EUCAST指南(克拉维酸的固定浓度)。并行,通过圆盘扩散重新测试了这些分离株的敏感性,根据EUCAST指南。对237个分离株中的233个成功进行了全基因组测序。在237个分离株中只有130个(55.0%),根据EUCAST和CLSI标准进行的测试对阿莫西林/克拉维酸的MIC值相同.在237个分离株中的64个(27.0%),MIC值偏离了一个稀释度;在38(16.0%)中,两次稀释;五次(2.1%),三次稀释。从这107个不一致的结果中,根据EUCAST方法进行的测试显示,在93个大肠杆菌菌株中(94.1%)具有更多的抗性。此外,与CLSI测试程序相比,根据EUCAST指南进行的表型敏感性测试倾向于与β-内酰胺酶基因的存在更好地相关.这项研究强调了在进行阿莫西林/克拉维酸的MIC测试时,EUCAST和CLSI方法之间的低一致性。当应用EUCAST指南时,更多菌株被归类为抗性。EUCAST和CLSI之间的低一致性得到了WGS的证实,因为大多数EUCAST抗性/CLSI敏感分离株都含有β-内酰胺酶基因。
    In our tertiary care center, the reported susceptibility of E. coli blood isolates to amoxicillin/clavulanic acid exceeded 90% in 2005 and showed a progressive decrease to 50% by 2017. In this study, we investigate whether there is a real increase in resistant E. coli strains or if this apparent decline in reported susceptibility might be attributed to the substitution of CLSI by EUCAST guidelines in 2014. We randomly selected 237 E. coli blood isolates (stored at - 80 °C) from 1985 to 2018 and reassessed their MIC values, applying both the CLSI (fixed ratio of clavulanic acid) and EUCAST guidelines (fixed concentration of clavulanic acid). In parallel, the susceptibility of these isolates was retested by disk diffusion, according to the EUCAST guidelines. Whole genome sequencing was successfully performed on 233 of the 237 isolates. In only 130 of the 237 isolates (55.0%), testing according to the EUCAST and CLSI criteria delivered identical MIC values for amoxicillin/clavulanic acid. In 64 of the 237 isolates (27.0%), the MIC values diverged one dilution; in 38 (16.0%), two dilutions; and in five (2.1%), three dilutions. From these 107 discrepant results, testing according to EUCAST methodology revealed more resistant profiles in 93 E. coli strains (94.1%). Also, phenotypical susceptibility testing according to EUCAST guidelines tends to correlate better with the presence of beta-lactamase genes compared to CLSI testing procedure. This study highlights the low agreement between EUCAST and CLSI methodologies when performing MIC testing of amoxicillin/clavulanic acid. More strains are categorized as resistant when EUCAST guidelines are applied. The low agreement between EUCAST and CLSI was confirmed by WGS, since most of EUCAST resistant/CLSI sensitive isolates harbored beta-lactamase genes.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    我们目前对RNA病毒自然进化的理解主要来自共识水平的遗传分析,该分析忽略了包含宿主内病毒种群的多种突变群。病毒突变群的广度和组成影响病毒的适应性和适应性,并且群体可塑性的能力可能对于在分类学上不同的宿主之间循环的节肢动物传播的病毒(虫媒病毒)尤为重要。尽管如此,缺乏突变群和共有序列的选择压力和遗传特征之间的关系的表征。为了澄清这一点,我们分析了以前产生的全基因组,从纽约州1999-2018年从鸟类组织或蚊子中分离出的548个西尼罗河病毒样本的深度测序数据.分析了共有水平(宿主间)和少数水平(宿主内)的核苷酸和氨基酸序列,并且在整个基因组中计算每个位置的多样性,以评估单个基因和宿主的少数和共有序列之间的关系。我们的结果表明,共有序列是整体遗传多样性的无能代表。鉴定了独特的宿主和基因特异性标记和选择压力。这些数据表明,对宿主内部和宿主之间的虫媒病毒进化和适应的准确和全面的理解需要考虑少数基因型。
    Our current understanding of the natural evolution of RNA viruses comes largely from consensus level genetic analyses which ignore the diverse mutant swarms that comprise within-host viral populations. The breadth and composition of viral mutant swarms impact viral fitness and adaptation, and the capacity for swarm plasticity is likely to be particularly important for arthropod-borne viruses (arboviruses) that cycle between taxonomically divergent hosts. Despite this, characterization of the relationship between the selective pressures and genetic signatures of the mutant swarm and consensus sequences is lacking. To clarify this, we analyzed previously generated whole genome, deep-sequencing data from 548 West Nile virus samples isolated from avian tissues or mosquitoes in New York State from 1999-2018. Both consensus level (interhost) and minority level (intrahost) nucleotide and amino acid sequences were analyzed, and diversity at each position was calculated across the genome in order to assess the relationship between minority and consensus sequences for individual genes and hosts. Our results indicate that consensus sequences are an inept representation of the overall genetic diversity. Unique host and gene-specific signatures and selective pressures were identified. These data demonstrate that an accurate and comprehensive understanding of arbovirus evolution and adaptation within and between hosts requires consideration of minority genotypes.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

  • 文章类型: Journal Article
    严重急性呼吸系统综合症冠状病毒-2(SARS-CoV-2)是对人类的威胁,并在全球范围内造成了大流行。每天都有成千上万的人受到SARS-CoV-2病毒的影响;印度也不例外。在这种情况下,毫无疑问,疫苗是遏制COVID-19大流行浪潮的一级预防策略。在这方面,SARS-CoV-2的全基因组分析对于了解其遗传变异性很重要。这促使我们使用多种序列比对技术分析566个印度SARS-CoV-2序列。ClustalW,肌肉,ClustalO和MAFFT进行比对,并随后将突变列表识别为替换,删除,插入和SNP。此后,这些结果的共识,称为一致性多序列比对(CMSA),准备有突变的最终列表,以便可以保留所有四种比对技术的优点。分析显示767、2025和54个独特的替代,印度SARS-CoV-2基因组中的缺失和SNP。更确切地说,在54个SNP中,4个SNP存在于接近60%的病毒群体中。本实验结果可用于病毒分类,设计和定义印度人口的疫苗剂量。
    Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is a threat to the human population and has created a worldwide pandemic. Daily thousands of people are getting affected by the SARS-CoV-2 virus; India being no exception. In this situation, there is no doubt that vaccine is the primary prevention strategy to contain the wave of COVID-19 pandemic. In this regard, genome-wide analysis of SARS-CoV-2 is important to understand its genetic variability. This has motivated us to analyse 566 Indian SARS-CoV-2 sequences using multiple sequence alignment techniques viz. ClustalW, MUSCLE, ClustalO and MAFFT to align and subsequently identify the lists of mutations as substitution, deletion, insertion and SNP. Thereafter, a consensus of these results, called as Consensus Multiple Sequence Alignment (CMSA), is prepared to have the final list of mutations so that the advantages of all four alignment techniques can be preserved. The analysis shows 767, 2025 and 54 unique substitutions, deletions and SNPs in Indian SARS-CoV-2 genomes. More precisely, out of 54 SNPs, 4 SNPs are present close to the 60% of the virus population. The results of this experiment can be useful for virus classification, designing and defining the dose of vaccine for the Indian population.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

  • 文章类型: Journal Article
    Strongyloitiasis是一种土壤传播的蠕虫病,which,尽管目前估计有多达3.7亿人感染了致病因子,类线虫,经常被忽视。最近在东南亚和澳大利亚进行的分子分类学研究,表明狗可以携带同样基因型的胸骨链球菌,也可以感染人类,除了可能是狗特有的类圆线虫物种。这表明胸骨链球菌从狗到人类的人畜共患传播的可能性。尽管在人类以外的任何宿主中都没有报道过自然S.stercoralis感染,非人灵长类动物和狗,不能排除其他尚未识别的动物水库。分子研究还表明,人类携带不同基因型的胸骨链球菌。因此,它们的分类地位以及它们的致病潜力是否不同的问题仍然存在。因此,从世界各地获得有关Stercoralis种群的分子遗传/基因组信息将非常重要。实现这一目标的一种方法(几乎没有额外的采样工作)是在诊断工作过程中遇到S.stercoralis的人保留一些标本以进行分子分析。在这里,我们提供了隔离的指导方针,保存,在核18SrDNA和线粒体cox1基因座进行基因分型,以及对单个胸骨链球菌蠕虫的全基因组测序。由于在许多情况下,在发现S.stercoralis的地点和时间不可能或不希望进行全面分析,我们强调何时以及如何保存样品,储存和运输以备日后分析。我们希望这将有利于并鼓励进行实地研究或诊断的研究人员收集和保存S.stercoralis进行分子遗传/基因组分析,并自行分析或使其可供他人进一步分析。
    Strongyloidiasis is a soil-borne helminthiasis, which, in spite of the up to 370 million people currently estimated to be infected with its causing agent, the nematode Strongyloides stercoralis, is frequently overlooked. Recent molecular taxonomic studies conducted in Southeast Asia and Australia, showed that dogs can carry the same genotypes of S. stercoralis that also infect humans, in addition to a presumably dog-specific Strongyloides species. This suggests a potential for zoonotic transmission of S. stercoralis from dogs to humans. Although natural S. stercoralis infections have not been reported in any host other than humans, non-human primates and dogs, other as yet unidentified animal reservoirs cannot be excluded. Molecular studies also showed that humans carry rather different genotypes of S. stercoralis. As a result, their taxonomic status and the question of whether they differ in their pathogenic potential remains open. It would therefore be very important to obtain molecular genetic/genomic information about S. stercoralis populations from around the world. One way of achieving this (with little additional sampling effort) would be that people encountering S. stercoralis in the process of their diagnostic work preserve some specimens for molecular analysis. Here we provide a guideline for the isolation, preservation, genotyping at the nuclear 18S rDNA and the mitochondrial cox1 loci, and for whole genome sequencing of single S. stercoralis worms. Since in many cases the full analysis is not possible or desired at the place and time where S. stercoralis are found, we emphasize when and how samples can be preserved, stored and shipped for later analysis. We hope this will benefit and encourage researchers conducting field studies or diagnostics to collect and preserve S. stercoralis for molecular genetic/genomic analyses and either analyze them themselves or make them available to others for further analysis.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

公众号